The FirstTake Podcast – Does a paradigm shift in breast cancer beckon?

Update: 2022-02-24

Description

This week FirstWord Pharma PLUS editors Michael Flanagan, Virginia Li and Simon King discuss confirmation of positive top-line data for AstraZeneca and Daiichi Sankyo’s Enhertu in HER2 ‘low’ breast cancer, the implications stemming from Amicus Therapeutics’ decision to abort a gene-therapy spin out and whether GlaxoSmithKline and Sanofi’s long-awaited COVID-19 vaccine has arrived too late to make a meaningful impact on the pandemic.

Comments

In Channel

The FirstTake Podcast – NK Cell therapy, CAR-T in solid tumours and our early take on Q1 earnings season

2022-04-2812:49

The FirstTake Podcast – Previewing AACR

2022-04-0411:12

The FirstTake Podcast – The FDA faces up to a tricky ALS regulatory decision, Roche’s TIGIT setback and more…

2022-03-3116:38

The FirstTake Podcast – A landmark cancer approval, Pfizer’s Arena deal delivers and the expert view on recent breast cancer developments

2022-03-2412:55

The FirstTake Podcast – Sanofi’s breast cancer hopeful fails to deliver

2022-03-1714:50